Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online March 23, 2006
OPEN ACCESS ARTICLE
This Article
Free via Open Access: OA
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow HTML Page - index.htslp
Right arrow HTML Page - index.htslp
Right arrowOA All Versions of this Article:
2005-0592v1
2005-0592v2
24/7/1628    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hall, V. J.
Right arrow Articles by Stojkovic, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hall, V. J.
Right arrow Articles by Stojkovic, M.
Submitted on November 26, 2005
Accepted on March 17, 2006

Technology Development

Using therapeutic cloning to fight human disease: A conundrum or reality?

Vanessa J. Hall 1*, Petra Stojkovic 2, Miodrag Stojkovic 2

1 Neuronal Survival Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden
2 Centre for Stem Cell Biology and Regenerative Medicine PRINCIPE FELIPE Centro de Investigacion, Valencia, Spain

* To whom correspondence should be addressed. E-mail: vanessa.hall{at}med.lu.se.


  Abstract

The development and transplantation of autologous cells derived from nuclear transfer embryonic stem cell (NT-ESC) lines to treat patients suffering disease has been coined Therapeutic Cloning. Human NT is still a developing field, with further research required to improve somatic cell NT, human embryonic stem cell (hESC) differentiation, in order to deliver safe and effective cell replacement therapies. Furthermore, implications of transferring mitochondrial heteroplasmic cells may harbour aberrant epigenetic gene expression profiles, which is of concern. The production of human NT-ESC lines also remains plagued by ethical dilemmas, societal concerns and controversies. Recently, a number of alternate therapeutic strategies have been proposed to circumvent the moral implications surrounding human nuclear transfer. It will be critical to overcome these biological, legislative and moral restraints in order to maximize the potential of this therapeutic strategy and to alleviate human disease.




This article has been cited by other articles:


Home page
 Stem CellsHome page
D. W. Han, J. T. Do, L. Gentile, M. Stehling, H. T. Lee, and H. R. Scholer
Pluripotential Reprogramming of the Somatic Genome in Hybrid Cells Occurs with the First Cell Cycle
Stem Cells, February 1, 2008; 26(2): 445 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. J. French, C. A. Adams, L. S. Anderson, J. R. Kitchen, M. R. Hughes, and S. H. Wood
Development of Human Cloned Blastocysts Following Somatic Cell Nuclear Transfer with Adult Fibroblasts
Stem Cells, February 1, 2008; 26(2): 485 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
K. Triller Vrtovec and B. Vrtovec
Commentary: Is Totipotency of a Human Cell a Sufficient Reason to Exclude Its Patentability Under the European Law?
Stem Cells, December 1, 2007; 25(12): 3026 - 3028.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.